Your session is about to expire
← Back to Search
Ultrasound Therapy
ExAblate for Essential Tremor (ET004 Trial)
N/A
Waitlist Available
Led By Nir Lipsman
Research Sponsored by InSightec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
The objective of this study is to evaluate the safety and feasibility of Auto Focusing (AF) echo imaging using the ExAblate Neuro system
Eligible Conditions
- Essential Tremor
- Tremor
- Neurologic Symptoms
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ExAblate 4000 SystemExperimental Treatment1 Intervention
ExAblate Neuro system to perform AF echo imaging in treatment of Essential Tremor
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ExAblate
2010
N/A
~130
Find a Location
Who is running the clinical trial?
InSightecLead Sponsor
91 Previous Clinical Trials
3,772 Total Patients Enrolled
12 Trials studying Essential Tremor
1,059 Patients Enrolled for Essential Tremor
Nir LipsmanPrincipal InvestigatorSunnybrook Health Science Centre
Share this study with friends
Copy Link
Messenger